Optomed

1.54 EUR

+2.95 %

5,665 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+2.95 %
-31.03 %
-42.50 %
-59.20 %
-58.04 %
-63.07 %
-53.11 %
-87.18 %
-66.42 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
33M EUR
Turnover
675.34K EUR
P/E (adj.) (26e)
-11.38
EV/EBIT (adj.) (26e)
-8.43
P/B (26e)
1.56
EV/S (26e)
1.59
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
07.05.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 07.05.2026

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8
2026

Interim report Q2'26

6.11
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Optomed Q4'25 preview: Fokus på forventninger
Analyst Comment by
Juha Kinnunen

Optomed Q4'25 preview: Fokus på forventninger

Optomed offentliggør sit Q4 regnskab næste tirsdag. Hovedfokus i regnskabet er rettet mod omsætningsvækstprognosen for 2026, som vi forventer vil være i form af "stærk vækst". Vores opmærksomhed i regnskabsmeddelelsen er især rettet mod den kommercielle udvikling af vækstfaktorerne i Udstyr-segmentet, såsom Aurora AEYE-løsningen og Optomed Lumo.

Optomed
Forum discussions
To wrap up the end of May, another block trade: Optomed: Block trade at 18:32. 231,001 shares were sold at 1.538 euros per share, for a total value of 355,280 euros.
yesterday
by Mr. Stock
8
Based on Optomed’s own website, which was updated in March, the ESG work is already well underway. It shouldn’t take much longer to complete the ESG reporting required by the partner. Optomed Yritysvastuu Ympäristö- ja yhteiskuntavastuuseen sekä hallintotapaan liittyvät asiat (ESG...
yesterday
by Sheikki
8
Apparently, projects are also being prepared in Portugal. Iiro, who is tagged in the post, is the ICT Manager at Optomed. Mona Health’s AI is likely being used. Image management is handled through Sectra. That pretty much puts the whole package together.
5/29/2026, 4:18 AM
by Sheikki
7
In the closing auction, nearly 150k also went at the same price, totaling approximately 380k shares. I wonder if OP or Danske sold off the rest of their Optomed holdings after that active dumping. It’s a shame we probably won’t see who the buyer was from Monday’s shareholder list...
yesterday
by Bob Fleming
4
In ESG reporting, that “G” component probably causes the most to chew on. Environment and Social are a breeze for a health technology company, but as for point G: Optomed is a small company operating in a new industry with small revenue. If they need to take a stand on how the Governance...
5/29/2026, 7:02 AM
by Dr.Feelgood
4
If you want to see today’s trades, it’s not worth heading there as early as Monday. There were many index changes today; I’m sure the Optomed trades are related to the same thing.
yesterday
by Critter
2
It’s good that the much-maligned software side is also busy around the world. It’s a pity that at least on the table, a Canon CR-2 camera seems to be featured instead of Optomed hardware.
5/29/2026, 4:50 AM
2
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.